16 most recent filings and news items mentioning MRK. Updated every 60 seconds.
curl "https://api.brieftape.com/v1/tickers/MRK/news?limit=20"
Pull MRK filings straight into your trading bot, model, or app.
Get an API key — free tier: 10,000 calls/dayMerk Announces Topline Results From Its Phase 3 ATLAS-UC Induction-Only Study Evaluating Tulisokibart In Patients With Moderately To Severely Active UC; Study Successfully Met Its Primary Endpoint Of Clinical Remission
View filing at SEC.gov →Merck Reports Topline Results From Phase 3 ATLAS-UC Induction-Only Study Evaluating Tulisokibart
View filing at SEC.gov →Phase 3 ATLAS-UC induction-Only Study Met Primary Endpoint
View filing at SEC.gov →Merck Scores Key Phase 3 Win For Novel Ulcerative Colitis Therapy
View filing at SEC.gov →Merck Announces FDA Approval Of An Expanded Indication For Its Pneumococcal Vaccine CAPVAXIVE
View filing at SEC.gov →FDA Expands Merck Pneumococcal Shot Label To Include At-Risk Children And Teens
View filing at SEC.gov →Protillion Biosciences Signs Discovery Collaboration, License Deal With Merck To Integrate Its Platform With Merck's Expertise For Novel Therapeutic Candidates Discovery
View filing at SEC.gov →Merck's Belzutifan In Combination With Pembrolizumab Receives FDA Approval To Treat Adults With Renal Cell Carcinoma
View filing at SEC.gov →Merck To Acquire TARGAN, A Maker Of Poultry Biodevice Solutions; Terms Not Disclosed
View filing at SEC.gov →7 Health Care Stocks With Whale Alerts In Today's Session
View filing at SEC.gov →Merck CEO Says Co Will Focus On $1 Billion To $15 Billion "Sweet Spot" For M&A
View filing at SEC.gov →Merck Exec Says "We Have Every Indication That The National Priority Voucher Given For Enlicitide Is Moving Forward"; Says "We Are Interested In Looking At The Broader Obesity Space, But Less About Obesity Than Its Comorbidities"
View filing at SEC.gov →Gilead And Merck End Trodelvy-Keytruda Lung Cancer Trial
View filing at SEC.gov →Merck And Gilead Discontinue Phase 3 KEYNOTE-D46/EVOKE-03 Trial After Trodelvy–KEYTRUDA Combination Fails To Achieve Statistically Significant Progression-Free Survival Benefit In First-Line Metastatic NSCLC
View filing at SEC.gov →Gilead And Merck Report Phase 3 Results For Once-Weekly Oral HIV Regimen Islatravir/Lenacapavir; Meets Week 48 Endpoints In ISLEND-1 And ISLEND-2 Trials
View filing at SEC.gov →Merck & Co. authorized the issuance of up to $500 million in floating rate notes maturing in May 2028 under its existing indenture. The debt offering represents standard corporate financing activity for the pharmaceutical company.
View filing at SEC.gov →